adminの記事一覧

Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury.

Crit Care Med. 38(10): 2037-2042, 2010PubMed

Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.

Eur J Clin Invest. 40(2): 95-102, 2010.PubMed

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.

Diabetes Care. 33(6): 1320-1324, 2010.PubMed

Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.

Am J Med Sci. 339(2): 157-163, 2010.PubMed

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.

Kidney Blood Press Res. 33(3): 213-220, 2010.PubMed

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

Eur J Clin Invest. 40(9): 790-796, 2010.PubMed

Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.

Am J Pathol. 174(6): 2096-2106, 2009.PubMed

Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.

Am J Pathol. 174(4): 1203-1211, 2009.PubMed

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Nephron Clin Pract. 112(3): c148-156, 2009.PubMed

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Diabetes Care. 32(9): 1684-1688, 2009.PubMed